Risperidone-Induced Adverse Reactions in Children and Adolescents: A Literature Overview

Sinzig, J., Dopfner, M., Lehmkuhl, G., Uebel, H., Schmeck, K., Poustka, F., et al. (2007). Long-acting methylphenidate has an effect on aggressive behavior in children with attentiondeficit/hyperactivity disorder. Journal of Child and Adolescent Psychopharmacology, 17(4), 421-432. Snyder, R., Turgay, A., et al. (2002). Effects of risperidone on conduct and disruptive behavior disorders in children with subaverage IQs. Journal of the American Academy of Child and Adolescent Psychiatry, 41(9), 1026-1036.

[1]  B. Franke,et al.  Risperidone-induced weight gain in referred children with autism spectrum disorders is associated with a common polymorphism in the 5-hydroxytryptamine 2C receptor gene. , 2010, Journal of child and adolescent psychopharmacology.

[2]  A. Tufan,et al.  Six months of treatment with risperidone may be associated with nonsignificant abnormalities of liver function tests in children and adolescents: a longitudinal, observational study from Turkey. , 2010, Journal of child and adolescent psychopharmacology.

[3]  A. Rosenbloom.  Hyperprolactinemia with Antipsychotic Drugs in Children and Adolescents , 2010, International journal of pediatric endocrinology.

[4]  Jacqueline L Johnson,et al.  Double-blind maintenance safety and effectiveness findings from the Treatment of Early-Onset Schizophrenia Spectrum (TEOSS) study. , 2010, Journal of the American Academy of Child and Adolescent Psychiatry.

[5]  J. Vakhrusheva,et al.  Risperidone associated weight, leptin, and anthropometric changes in children and adolescents with psychotic disorders in early treatment , 2010, Human psychopharmacology.

[6]  M. Copenhaver,et al.  A 6-week, randomized, double-blind, placebo-controlled study of the efficacy and safety of risperidone in adolescents with schizophrenia. , 2009, Journal of child and adolescent psychopharmacology.

[7]  E. Spina,et al.  Short- and long-term effects on prolactin of risperidone and olanzapine treatments in children and adolescents , 2009, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[8]  M. DelBello,et al.  Risperidone for the treatment of acute mania in children and adolescents with bipolar disorder: a randomized, double-blind, placebo-controlled study. , 2009, Bipolar disorders.

[9]  Barbara Napolitano,et al.  Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents. , 2009, JAMA.

[10]  Alessandro Zuddas,et al.  Antipsychotics in children and adolescents: Increasing use, evidence for efficacy and safety concerns , 2009, European Neuropsychopharmacology.

[11]  Del D. Miller,et al.  Variants of the dopamine D2 receptor gene and risperidone-induced hyperprolactinemia in children and adolescents , 2009, Pharmacogenetics and genomics.

[12]  S. Kuperman,et al.  Weight gain and metabolic abnormalities during extended risperidone treatment in children and adolescents. , 2009, Journal of child and adolescent psychopharmacology.

[13]  Ann E. Maloney,et al.  Double-blind comparison of first- and second-generation antipsychotics in early-onset schizophrenia and schizo-affective disorder: findings from the treatment of early-onset schizophrenia spectrum disorders (TEOSS) study. , 2008, The American journal of psychiatry.

[14]  B. Herpertz-Dahlmann,et al.  Weight gain in children and adolescents during 45 weeks treatment with clozapine, olanzapine and risperidone , 2008, Journal of Neural Transmission.

[15]  G. Pandina,et al.  Treating disruptive behavior disorders with risperidone: a 1-year, open-label safety study in children and adolescents. , 2008, Journal of child and adolescent psychopharmacology.

[16]  C. Arango,et al.  Metabolic and hormonal side effects in children and adolescents treated with second-generation antipsychotics. , 2008, The Journal of clinical psychiatry.

[17]  Fariz A. Rani,et al.  Epidemiologic Features of Antipsychotic Prescribing to Children and Adolescents in Primary Care in the United Kingdom , 2008, Pediatrics.

[18]  H. Ankarali,et al.  Risperidone and liver function tests in children and adolescents: A short-term prospective study , 2008, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[19]  C. McDougle,et al.  Effects of Short- and Long-Term Risperidone Treatment on Prolactin Levels in Children with Autism , 2007, Biological Psychiatry.

[20]  J. Buitelaar,et al.  Prolactin Release in Children Treated With Risperidone: Impact and Role of CYP2D6 Metabolism , 2007, Journal of clinical psychopharmacology.

[21]  V. Bhatara,et al.  Patterns and determinants of antipsychotic prescribing in children and adolescents, 2003–2004* , 2007, Current medical research and opinion.

[22]  B. Herpertz-Dahlmann,et al.  Weight gain associated with clozapine, olanzapine and risperidone in children and adolescents , 2007, Journal of Neural Transmission.

[23]  C. McDougle,et al.  Dietary status and impact of risperidone on nutritional balance in children with autism: A pilot study , 2006, Journal of intellectual & developmental disability.

[24]  H. McCarthy,et al.  Body fat measurements in children as predictors for the metabolic syndrome: focus on waist circumference , 2006, Proceedings of the Nutrition Society.

[25]  J. Buitelaar,et al.  Neuropsychological effects of risperidone in children with pervasive developmental disorders: a blinded discontinuation study. , 2006, Journal of child and adolescent psychopharmacology.

[26]  C. Correll,et al.  Endocrine and metabolic adverse effects of psychotropic medications in children and adolescents. , 2006, Journal of the American Academy of Child and Adolescent Psychiatry.

[27]  J. Staller.  The effect of long-term antipsychotic treatment on prolactin. , 2006, Journal of child and adolescent psychopharmacology.

[28]  Carmen Moreno,et al.  National trends in the outpatient treatment of children and adolescents with antipsychotic drugs. , 2006, Archives of general psychiatry.

[29]  J. Buitelaar,et al.  A randomized, double-blind, placebo-controlled study of risperidone maintenance treatment in children and adolescents with disruptive behavior disorders. , 2006, The American journal of psychiatry.

[30]  C. McDougle,et al.  Acute and long-term safety and tolerability of risperidone in children with autism. , 2005, Journal of child and adolescent psychopharmacology.

[31]  J. Hellings,et al.  Risperidone-induced prolactin elevation in a prospective study of children, adolescents, and adults with mental retardation and pervasive developmental disorders. , 2005, Journal of child and adolescent psychopharmacology.

[32]  J. Buitelaar,et al.  Long-term effects of risperidone in children with autism spectrum disorders: a placebo discontinuation study. , 2005, Journal of the American Academy of Child and Adolescent Psychiatry.

[33]  J. Biederman,et al.  Open-Label, 8-Week Trial of Olanzapine and Risperidone for the Treatment of Bipolar Disorder in Preschool-Age Children , 2005, Biological Psychiatry.

[34]  S. Faraone,et al.  An open-label trial of risperidone in children and adolescents with bipolar disorder. , 2005, Journal of child and adolescent psychopharmacology.

[35]  John C. Maxwell,et al.  The Choice Is Yours , 2005 .

[36]  R. Findling,et al.  Risperidone in children with disruptive behavior disorders and subaverage intelligence: a 1-year, open-label study of 504 patients. , 2005, Journal of the American Academy of Child and Adolescent Psychiatry.

[37]  I. Smith,et al.  Risperidone in the Treatment of Disruptive Behavioral Symptoms in Children With Autistic and Other Pervasive Developmental Disorders , 2004, Pediatrics.

[38]  E. Spina,et al.  Risperidone treatment of children with autistic disorder: effectiveness, tolerability, and pharmacokinetic implications. , 2004, Journal of child and adolescent psychopharmacology.

[39]  M. Aman,et al.  Discontinuation of Risperidone and Reversibility of Weight Gain in Children with Disruptive Behavior Disorders , 2004, Clinical pediatrics.

[40]  R. Findling,et al.  Long-term, open-label study of risperidone in children with severe disruptive behaviors and below-average IQ. , 2004, The American journal of psychiatry.

[41]  J. Lieberman,et al.  A Pilot Study of Risperidone, Olanzapine, and Haloperidol in Psychotic Youth: A Double-Blind, Randomized, 8-Week Trial , 2004, Neuropsychopharmacology.

[42]  M. Schmidt,et al.  Risperidone-associated steatohepatitis and excessive weight-gain. , 2004, Pharmacopsychiatry.

[43]  C. Binder,et al.  Long-term safety and efficacy of risperidone for the treatment of disruptive behavior disorders in children with subaverage IQs. , 2002, Pediatrics.

[44]  C. McDougle,et al.  Risperidone in children with autism and serious behavioral problems. , 2002, The New England journal of medicine.

[45]  G. Maislin,et al.  Risperidone treatment in children and adolescents with autism: short- and long-term safety and effectiveness. , 2002, Journal of the American Academy of Child and Adolescent Psychiatry.

[46]  J. Buitelaar,et al.  A randomized controlled trial of risperidone in the treatment of aggression in hospitalized adolescents with subaverage cognitive abilities. , 2001, The Journal of clinical psychiatry.

[47]  A. Cosenza,et al.  Prolactin levels in young children with pervasive developmental disorders during risperidone treatment. , 2001, Journal of child and adolescent psychopharmacology.

[48]  P. Muglia,et al.  Long-term risperidone for pervasive developmental disorder: efficacy, tolerability, and discontinuation. , 2000, Journal of child and adolescent psychopharmacology.

[49]  S. Kumra,et al.  Case study: risperidone-induced hepatotoxicity in pediatric patients. , 1997, Journal of the American Academy of Child and Adolescent Psychiatry.